drugset

Drugs / CD19 and CD22 targeted CAR-T cells

Follow last change May 2023 re-read 3 minutes ago

CD19 and CD22 targeted CAR-T cells

Cell therapy targets CD19, CD22

Developed for: B-cell non-Hodgkin lymphoma
Investigated by: 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China · Chongqing University Cancer Hospital · Gracell Biotechnologies (Shanghai) Co., Ltd. · Tang-Du Hospital · The Affiliated Hospital Of Guizhou Medical University · The General Hospital of Western Theater Command
+1 more
· Xinqiao Hospital of Chongqing

Trials 1

today NCT04303247 · Ph 0

202120222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 0	NCT04303247	May 2020 → May 2021	B-cell non-Hodgkin lymphoma	Xinqiao Hospital of Chongqing	Unknown	No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	CD19 and CD22 targeted CAR-T cells	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04303247 ↗
Modality	Cell therapy	“CD19 and CD22 targeted CAR-T cell therapy” NCT04303247 ↗
Target	CD19	“The T cells aphesis from subjects then been manufactured to express CAR to binding CD19 and CD22 on B-cell lymphoma.” NCT04303247 ↗
Target	CD22	“The T cells aphesis from subjects then been manufactured to express CAR to binding CD19 and CD22 on B-cell lymphoma.” NCT04303247 ↗